PMID- 28802512
OWN - NLM
STAT- MEDLINE
DCOM- 20170914
LR  - 20181202
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 120
IP  - 7
DP  - 2017 Oct 1
TI  - Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from 
      CHAMPION PHOENIX).
PG  - 1043-1048
LID - S0002-9149(17)31104-9 [pii]
LID - 10.1016/j.amjcard.2017.06.042 [doi]
AB  - Cangrelor is approved for use during percutaneous coronary intervention (PCI) and 
      is administered with different parenteral anticoagulants. We examined the 
      efficacy and safety of cangrelor in the subgroup of patients who received 
      unfractionated heparin (UFH) during PCI in the modified intention-to-treat 
      population of the randomized CHAMPION PHOENIX trial (cangrelor vs clopidogrel; 
      n = 10,939). The primary efficacy end point was the composite of death, 
      myocardial infarction, ischemia-driven revascularization, or stent thrombosis 
      (ST) at 48 hours. The key secondary efficacy end point was ST. UFH was used in 
      69.2% (7,569/10,939) of patients. In the UFH subgroup, cangrelor reduced the 
      primary composite efficacy end point at 48 hours compared with clopidogrel (4.8% 
      vs 5.9%; odds ratio [OR] 0.80 [0.65 to 0.98]; p = 0.03). Cangrelor consistently 
      reduced ST at 2 hours (0.7% vs 1.3%; OR 0.56 [0.35 to 0.90]; p = 0.01) and 
      48 hours (0.9% vs 1.4%; OR 0.70 [0.45 to 1.07]; p = 0.10). There was no 
      difference in GUSTO (Global Use of Strategies to Open Occluded Coronary 
      Arteries)-defined severe or life-threatening bleeding (0.1% vs 0.1%; OR 1.24 
      [0.33 to 4.61]; p = 0.75) or blood transfusion requirement at 48 hours (0.4% vs 
      0.2%; OR 1.87 [0.83 to 4.21]; p = 0.12). In conclusion, cangrelor reduces early 
      ischemic periprocedural complications without increasing severe bleeding compared 
      with clopidogrel in patients undergoing PCI with UFH.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, 
      Boston, Massachusetts.
FAU - Harrington, Robert A
AU  - Harrington RA
AD  - Stanford University Medical School, Stanford, California.
FAU - Stone, Gregg W
AU  - Stone GW
AD  - Columbia University Medical Center and the Cardiovascular Research Foundation, 
      New York City, New York.
FAU - Steg, Ph Gabriel
AU  - Steg PG
AD  - FACT (French Alliance for Cardiovascular clinical Trials), DHU FIRE, INSERM Unite 
      1148, Universite Paris-Diderot, Paris, France; Hopital Bichat, 
      Assistance-Publique-Hopitaux de Paris, Paris, France; NHLI, Imperial College, 
      Royal Brompton Hospital, London, United Kingdom.
FAU - Gibson, C Michael
AU  - Gibson CM
AD  - Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, 
      Massachusetts.
FAU - Hamm, Christian W
AU  - Hamm CW
AD  - Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
FAU - Price, Matthew J
AU  - Price MJ
AD  - Scripps Clinic and Scripps Translational Science Institute, La Jolla, California.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - Science and Strategy Consulting Group, Basking Ridge, New Jersey.
FAU - Prats, Jayne
AU  - Prats J
AD  - The Medicines Company, Parsippany, New Jersey.
FAU - Mahaffey, Kenneth W
AU  - Mahaffey KW
AD  - Stanford University Medical School, Stanford, California.
FAU - White, Harvey D
AU  - White HD
AD  - Green Lane Cardiovascular Service, Auckland, New Zealand.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, 
      Boston, Massachusetts. Electronic address: dlbhattmd@post.harvard.edu.
CN  - CHAMPION PHOENIX Investigators
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170718
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - 6AQ1Y404U7 (cangrelor)
RN  - 9005-49-6 (Heparin)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Adenosine Monophosphate/administration & dosage/*analogs & derivatives
MH  - Aged
MH  - Anticoagulants/administration & dosage
MH  - Clopidogrel
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Intraoperative Period
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*therapy
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Postoperative Complications/*prevention & control
MH  - Retrospective Studies
MH  - Ticlopidine/administration & dosage/*analogs & derivatives
MH  - Treatment Outcome
EDAT- 2017/08/15 06:00
MHDA- 2017/09/15 06:00
CRDT- 2017/08/14 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/06/04 00:00 [revised]
PHST- 2017/06/20 00:00 [accepted]
PHST- 2017/08/15 06:00 [pubmed]
PHST- 2017/09/15 06:00 [medline]
PHST- 2017/08/14 06:00 [entrez]
AID - S0002-9149(17)31104-9 [pii]
AID - 10.1016/j.amjcard.2017.06.042 [doi]
PST - ppublish
SO  - Am J Cardiol. 2017 Oct 1;120(7):1043-1048. doi: 10.1016/j.amjcard.2017.06.042. 
      Epub 2017 Jul 18.